OncLive SOSS

Authors

Latest:

Paying It Forward: The Importance of Mentorship in a Medical Career

Beyond a lengthy list of accomplishments across the leukemia spectrum of treatment, Garcia-Manero holds the importance of mentorship as incredibly dear to his heart and a way to pass the torch forward in cancer care.

Reva K. Basho, MD

Latest:

Dr Basho on Treatment Considerations With ADCs in Breast Cancer

Reva K Basho, MD, discusses the use of antibody-drug conjugates across the spectrum of breast cancer subtypes at the 2023 Bridging the Gaps in Breast Cancer meeting.

Axel Merseburger, MD, PhD

Latest:

Approach to Collaborative Care in Bladder Cancer

The panel discusses the Large Urology Group Practice Association and provides insights on collaborative care approaches in bladder cancer.

Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center

Latest:

Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in Care

Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.

J. Bradley Elder, MD

Latest:

Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma

J. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.

Michael Serzan, MD

Latest:

Dr Serzan on the Rationale for Evaluating Botensilimab Plus Balstilimab in Advanced RCC

Michael Serzan, MD, discusses the rationale for evaluating botensilimab/balstilimab for patients with advanced renal cell carcinoma.

Richard Martin, MD, MPH

Latest:

Mentoring Oncologists in the Era of Social Distancing

Mentoring is critically important to the development of young academic hematology/oncology trainees.

Masahiro Tsuboi, MD, National Cancer Center Hospital East

Latest:

Dr Tsuboi on Updated Survival Results of the ADAURA Trial in Resectable NSCLC

Masahiro Tsuboi, MD, discusses the updated survival results of the phase 3 ADAURA trial in resectable EGFR-mutant non–small cell lung cancer.

Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute

Latest:

Novel Treatment Combinations in Chronic Lymphocytic Leukemia

Dr Brown and Dr Stilgenbauer provide their input on novel treatment options emerging for chronic lymphocytic leukemia.

Nicole D. Vincelette, PhD

Latest:

Dr Vincelette on MYC Expression in Myelofibrosis

Nicole D. Vincelette, PhD, discusses the role of MYC expression in a subgroup of triple-negative myeloproliferative neoplasms.

Anand Narayan, MD, PhD

Latest:

Dr Narayan on Variations in Breast Cancer Outcomes by Race

Anand Narayan, MD, PhD, discusses how outcomes differ between different subgroups of patients who are diagnosed with breast cancer, highlighting how these differences tie back to disparities in cancer care.

Sophia George, PhD

Latest:

Dr. George on Actionable Pathogenic Variants in Adults With Breast or Ovarian Cancers in the Caribbean

Sophia George, PhD, discusses actionable pathogenic variants in patients with breast cancer who live in the Caribbean.

Alexander I. Spira, MD, PhD

Latest:

A Phase 1 Clinical Trial Evaluating Monotherapy With Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF‑Altered Solid Tumors and NRAS-Mutant Melanoma

Alexander I. Spira, MD, PhD, shares new dose escalation data from the first-in-human Phase 1 KIN-2787 study of the pan-RAF inhibitor exarafenib in patients with BRAF-altered solid tumors or NRAS-mutant melanoma.

University of Miami Health System

Latest:

Expanding the Patient Pool for Immunotherapies

Although immune checkpoint inhibitors can yield dramatic results and give some patients many years of life, some patients do not yield benefit.

Samer Khaled, MD, City of Hope

Latest:

Narsoplimab Trial Results

The panel of transplant experts discuss the results of the phase 2 trial of narsoplimab and the pending FDA approval of this agent for treatment of transplant-associated of thrombotic microangiopathy.

Suthee Rapisuwon, MD

Latest:

Dr. Rapisuwon on Clinical Trial Barriers in the United States in Mucosal Melanoma

Suthee Rapisuwon, MD, discusses clinical trial barriers for patients with mucosal melanoma in the United States.

Sarah Elizabeth Yentz, MD

Latest:

Dr Yentz on Treatment Decisions in Favorable-Risk RCC

Sarah Elizabeth Yentz, MD, discusses treatment considerations in patients with favorable-risk renal cell carcinoma.

Beth Sandy, MSN, CRNP

Latest:

The Evolving Treatment Landscape in SCLC

Beth Sandy, MSN, CRNP, discusses the evolving treatment landscape in small cell lung cancer.

Sai Yendamuri, MD, FACS

Latest:

Investigators Seek to Resolve the “Obesity Paradox” in Lung Cancer

Smoking is associated with the most widely known cancer causing carcinogen across the world. However, a second, more insidious factor has been increasingly recognized for its role in promoting cancer growth: obesity.

Suresh S. Ramalingam, MD, FACP, FASCO

Latest:

Dr Ramalingam on Updates in Lung Cancer Following the 2024 ASCO Annual Meeting

Suresh S. Ramalingam, MD, FACP, FASCO, and Chandler H. Park, MD, FACP, discuss updates in non–small cell lung cancer at the 2024 ASCO Annual Meeting.